Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab Open-Label Extension in Alzheimer's Disease
NCT01127633Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2010
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 16
01
Overview
A Phase 3 trial of solanezumab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Dec 2010; status: terminated.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01127633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01127633.